Ellagic acid supplementation effect in patients with type 2 diabetes

Assessment the ellagic acid supplementation effect on glycemic status, insulin resistance, inflammatory factors, antioxidant status and expression of miR146-a in patients with type 2 diabetes: double blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N13

Enrollment

Registered

2019-09-24

Start date

2019-08-31

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Ellagic acid, a capsule 200 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flou

Eligibility

Sex/Gender

All

Age

24 Years to 55 Years

Inclusion criteria

Inclusion criteria: Men and women with with type 2 diabetes Willingness to work Age 25- 55 Non-modification of treatment and medications for at least the past 2 months Moderate physical activity

Exclusion criteria

Exclusion criteria: Insulin using Having diabetes for more than ten years Pregnancy and breastfeeding Patients with severe renal and hepatic dysfunction, Alcohol consumption

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;2 hours sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Glycosylated hemoglobin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Glutathione peroxidase enzyme. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Superoxide dismutase enzyme. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Expression of miR146-a. Timepoint: Before the intervention and after the intervention. Method of measurement: Real-Time PCR.;SIRT1. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Fetuin A. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;2 hours sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Glycosylated hemoglobin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Glutathione peroxidase enzyme. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Superoxide dismutase enzyme. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Expression of miR146-a. Timepoint: Before the intervention and after the intervention. Method of measurement: Real-Time PCR.;SIRT1. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Fetuin A. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 16, 2026